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ABSTRACT: Metformin is one of the most widely used oral anti-diabetic drugs currently considered
to be one of the first-choice drugs for Type 2 Diabetes mellitus (T2DM). However, some adverse drug
reactions (ADRs) were frequently observed with the treatment with Metformin and its combinations.
This study was planned to investigate the ADR profile of Metformin in Type 2 Diabetes mellitus
patients attending diabetic Out Patient Department (OPD) of a Tertiary care hospital, Kolkata. An
observational cross sectional study with diagnosed cases of Type 2 Diabetes mellitus both male and
female, with age group 30-60 years were randomly selected. Present study data revealed that, 61.60%
(154) out of 250 patients within age of 46-50 yrs had experienced maximum adverse drug reactions
where majorities belonged to female 70.12%. Occurrence of hyper acidity and flatulence (61.03%)
was high in patients treated with Metformin and its combinations, followed by weakness (29.87%),
dizziness (28.57%) and bodyache (20.77%) are other adverse reactions present in majority of patients.
Special attention must be provided by the medical professionals to prevent the possible occurrence of
ADRs in the patients treated with Metformin and its combinations. This may improve the adherence
of  Metformin by reducing the prevalence of  Metformin-induced ADRs.
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INTRODUCTION
The World Health Organization (WHO)
estimated that in the year 1995 there were 135
million diabetic individuals and this number
will increase to 300 million by the year 2025.
Considering the large population and increasing
prevalence of Diabetes mellitus of nearly 33
million diabetic subjects, the burden of diabetes
in India could be enormous (Ramachandran
et al.  2001).
Numerous studies have shown metformin to
be highly effective and safe in the treatment of
Type 2 Diabetes (De Fronzo and Goodman
1995, Johnson et al. 2002, UK Prospective
Diabetes Study group 1998). It is the only
currently available biguanide. Indeed, it is one
of the most widely used oral anti-diabetic drugs.
Metformin improves insulin resistance by
inhibiting gluconeogenesis and enhancing
peripheral glucose uptake through stimulation
of adenosine monophosphate (AMP)-activated
kinase  (Scarpello and Howlett 2008).
Metformin is the only anti-diabetic agent that
has been shown to reduce mortality in patients
with newly diagnosed Type 2 Diabetes and the
only anti-diabetic agent not shown to be
associated with increased morbidity and
mortality in patients with cardiac disease,
including heart failure (Johnson et al. 2002, UK
Prospective Diabetes Study group 1998, Eurich
et al. 2005, Smooke et al. 2005). It is the most
frequently prescribed drug given alone or in
combination with other drugs.
Metformin is generally well tolerated.
However, it is well known that Metformin
frequently causes adverse drug reactions
(ADRs) including gastrointestinal adverse
events, especially diarrhea (Nathan et al. 2009).
These ADRs occasionally leads to withdrawal
of Metformin treatment (Garber et al. 1997,
Belcher et al. 2005). Present study evaluated
the Metformin use pattern in patients of Type 2
Diabetes mellitus in a Tertiary care hospital in
Kolkata, West Bengal, India followed by
identification of the risk-factors related to ADRs
in the patients, treated with Metformin, to
ensure the appropriate use of Metformin.
MATERIALS   AND   METHODS
The study was carried out in the OPD of
R. G. Kar Medical College & Hospital, Kolkata,
West Bengal, India. This was an observational,
cross sectional study on diagnosed cases of
Type 2 Diabetes mellitus by random selection.
The prescriptions and medical reports were
collected from the patients & later evaluated.
Only those patients, following inclusion and
exclusion criteria attending Diabetes OPD and
Medicine OPD of R. G. Kar Medical College
& Hospital were requested to join this study,
and a written consent was taken from the
patients. A questionnaire was developed,
standardised and validated for this work. Ethical
clearance was taken from Institutional Ethics
Committee. A total of 250 patients were
included in the study.
Confirmed cases of Diabetes mellitus
Type 2 both male and female, age group
between 30-60 years; continuous and
uninterrupted treatment with Metformin and its
combination for at least one month, were
included in the study.
RESULTS   AND   DISCUSSION
Present study evaluated that maximum
number of patients were prescribed a dose
between 500-1000 mg of Metformin. This dose
was used extensively by both male and female
patients. Only 1.2% of patients had received a
dose more than 2500 mg of Metformin. The119
daily frequency of the drug in majority of
patients was 2  i.e. 43.2%, which is closely
followed by 3, with 41.6%.
The Fig.1 showed that 61.60% (154) out of
250 patients had experienced adverse drug
reaction and the rest 38.40% (96) experienced
no adverse drug reaction. The following
graphical presentation shows the pie-chart of
distribution of the total study population (n=250
patients) according to patients with ADR and
patients with No ADR.
Out of 154 patients with ADR, male patients
were 29.87% (46) and female patients were
70.12% (108). Therefore it was found that
majority of the patients who experienced ADRs
of Metformin were females.
Histogram in Fig.2 showed that patients
within age between 41-45 yrs and 46-50 yrs had
experienced more ADR’s. Patients within age
of 30-35 yrs had experienced minimum ADR’s
and patients within age of 46-50 yrs had
experienced maximum ADR’s.
Table 1 showed the list of adverse drug
reactions experienced by the 154 patients
treated with Metformin and its combinations.
This table clearly showed that the occurrence
of Hyper acidity and flatulence (61.03%) was
high in patients treated with Metformin and its
combinations, followed by weakness (29.87%),
dizziness (28.57%) and body ache (20.77%) are
other adverse reactions which were present in
certain majority of patients.
Body systems mostly Types of adverse drug No. of Percentage (n=154)
 affected by ADRs reactions  patients n=Total no. of Patients
Gastrointestinal system related Hyper acidity, Flatulence 94 61.03%
Diarrhea 24 15.58%
Abdominal discomfort 10 6.49%
Nausea & Vomiting 6 3.89%
Weight loss or Anorexia 3 1.94%
Respiratory system related Respiratory Distress 11 7.14%
Muscular-skeletal system related Muscular pain 20 12.98%
Numbness of hands 6 3.89%
Numbness of legs 7 4.54%
Body ache 32 20.77%
CNS related Weakness 46 29.87%
Dizziness 44 28.57%
Headache 5 3.24%
Immune system related Skin rash 1 0.64%
Table 1: Distribution of adverse drug reactions of Metformin & its combinations (n=154)
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Present study report showed that maximum
number of patients i.e. 42.8% of study
population, extensively received Metformin
dose between 500-1000 mg. The number of
daily dose of Metformin in majority (43.2%)
of total patients is 2. Similar report also
available from a study in Japan, which reflected
the dose of Metformin administered were 500
mg in 51.5% and 750 mg in 48.5% of the total
study population (Okayasu et al. 2012).
Out of 250 patients, 61.60% had experienced
adverse drug reaction and the rest 38.40%
experienced no adverse drug reaction. Among
the affected patients, male patients were 46
(29.87%) and female patients were
108(70.12%). Therefore it was found that
majority of patients who were taking Metformin
had experienced adverse drug reaction and
females were more prone to the ADRs. This
data is similar to other study in California where
it was also found that female and BMI also
became risk factors. It has been reported that
genders and body weight failed to affect the
pharmacokinetics of Metformin (Sambol et al.
1996). Thus, the further investigation would be
needed to understand these data.
Patients within age of 30-35 yrs had
experienced minimum ADR’s than patients
within age of 46-50 yrs had experienced
maximum ADR’s. This study data is an
agreement with some similar study in Japan
where the age less than 65 became a risk factor
although it is well accepted that reduced
functions of kidney, liver and other organs in
elderly subjects might strengthen the effect of
drugs (Okayasu et al. 2012). Our study report
also reveals that reduction of the occurrence of
these Metformin related ADRs with the increase
in age after 50 years. This is a unique finding
though it needs to be studied more extensively
to conclude about the reason behind.
There was no study from Kolkata, West
Bengal, India regarding the ADR related with
Metformin use and a few numbers of studies
were also conducted in India also. A study
regarding the risk factors associated with
Adverse Drug Reactions by Metformin in
Type 2 Diabetes mellitus from Japan showed
that most-frequently observed ADR was
Fig.1:  Distribution of the study population
according to ADR of Metformin.
Fig.2:  Distribution of the study population
(n=154) with ADR of Metformin according to
the age of the patient.121
diarrhea that occurred in 27% of patients, which
was consistent with the data 23.7% reported in
a large clinical trial, A Diabetes Outcome
Progression Trial (ADOPT) (Kahn et al. 2006).
ADR such as mild anorexia appeared in 3
patients (3%) without diarrhea. Nausea,
vomiting, hepatic and renal dysfunctions were
not observed. Although it is well known that
one of serious ADRs caused by Metformin is
lactic acidosis, (Salpeter et al. 2010) but no
ADRs related to lactic acidosis (ex. blood pH
etc.) were observed in the present study. But in
the present study occurrence of hyper acidity
and flatulence (61.03%) was high in patients
treated with Metformin and its combinations,
followed by weakness (29.87%), dizziness
(28.57%) and body ache (20.77%) are other
adverse reactions which were present in certain
majority of patients. In comparison with the
study in Japan less number of patients  i.e.
15.58% of total study population suffered from
Diarrhea and 1.94% from Anorexia.
There have been no detailed studies have
conducted in West Bengal as well as in India
about the ADRs related to Metformin and no
such report of serious adverse events to the drug
regulatory agencies or to the World Health
Organization Adverse Drug Reaction
Monitoring Centre. But the present study
reveals 61.60% of study population had
experienced adverse drug reaction related to the
use of Metformin. Therefore physicians should
take note of this adverse effect of Metformin,
since this drug is used extensively.
CONCLUSION
In conclusion, we found 61.60% of total
patients treated with Metformin experienced
Metformin- induced ADRs, occurrence of
hyper-acidity and flatulence as (61.03%) was
high in patients treated with Metformin and its
combinations. Some potential risk factors
involved are females, age of 46-50 yrs etc.
Therefore, checking the risk factors for
Metformin-induced adverse drug reactions may
aid medical professionals to prevent the
possible occurrence of ADRs to the patients.
Such type of study will improve the adherence
of Metformin by reducing the prevalence of
Metformin-induced ADRs.
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